<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="5766" end="5774" sStart="5757" offset="9" sid="r8.suggest.v.0756" wn="3" wnkey="suggest%2:32:02::" text="Evidence suggests that gain of function in PAX7 triggers neoplastic development by maintaining cells in a deregulated, undifferentiated and proliferative state, as is seen in alveolar rhabdomyosarcomas." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="5579" end="5586" sStart="null" offset="154" sid="r8.suggest.v.0640" wn="1" wnkey="suggest%2:32:00::" text="Although less frequent, 1p gains are also common to many tobacco-associated malignancies [ 11 13 14 15 16 ] . Work by Racz and colleagues suggest that PAX7 and ENO1 may be candidate oncogenes in this region [ 21 ] . PAX7 is part of a family of transcription factors known to be carcinogenic." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2156-3-22.anc" start="6655" end="6660" sStart="null" offset="0" sid="null" wn="3" wnkey="power%1:09:01::" text="Second, although it is amongst the largest studies analyzing of genetic differences based on carcinogen exposure, the sample size remains small limiting statistical &lt;b&gt;power&lt;/b&gt; to detect existing differences." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2156-3-22.anc" start="6655" end="6660" sStart="null" offset="0" sid="null" wn="3" wnkey="power%1:09:01::" text="Second, although it is amongst the largest studies analyzing of genetic differences based on carcinogen exposure, the sample size remains small limiting statistical &lt;b&gt;power&lt;/b&gt; to detect existing differences." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="4471" end="4477" sStart="null" offset="19" sid="r8.number.n.0268" wn="1" wnkey="number%1:07:00::" text="Although the total number and general pattern of abnormalities were similar, the prevalence of individual abnormalities was different based on the extent of tobacco/alcohol exposure as outlined in Figure 2. Amplification at 3q26-27 (p = 0.05) and gain of 1p (p = 0.03) were significantly more common in patients with carcinogen exposure." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="779" end="785" sStart="null" offset="22" sid="r9.level.n.0762" wn="1" wnkey="level%1:07:00::" text=", showing the highest levels of chromosomal sensitivity in lymphocytes after exposure to the clastogen bleomycin in HNSCC patients who were non-smokers [ 7 ] . Relatively few studies have directly investigated the impact of tobacco/alcohol exposure on the genetic composition of HNSCC." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2156-3-22.anc" start="10930" end="10935" sStart="null" offset="0" sid="null" wn="3" wnkey="image%1:06:00::" text="CGH was performed using previously published methods [ 11 ] . Seven to 10 separate metaphases were captured and processed using the Quantitative &lt;b&gt;Image&lt;/b&gt; Processing System (Quips Pathvysion system, Applied Imaging, Santa Clara, CA)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="2654" end="2661" sStart="null" offset="151" sid="r1.history.n.0085" wn="" wnkey="null" text="The study population was divided into 15 (21%) patients with limited and 56 patients (79%) with a significant tobacco/alcohol exposure history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="2654" end="2661" sStart="null" offset="151" sid="r1.history.n.0085" wn="1" wnkey="history%1:28:00::" text="The study population was divided into 15 (21%) patients with limited and 56 patients (79%) with a significant tobacco/alcohol exposure history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="2654" end="2661" sStart="null" offset="151" sid="r1.history.n.0085" wn="1" wnkey="history%1:28:00::" text="The study population was divided into 15 (21%) patients with limited and 56 patients (79%) with a significant tobacco/alcohol exposure history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="2654" end="2661" sStart="null" offset="151" sid="r1.history.n.0085" wn="2147483646" wnkey="null" text="The study population was divided into 15 (21%) patients with limited and 56 patients (79%) with a significant tobacco/alcohol exposure history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="5788" end="5796" sStart="null" offset="31" sid="r11.function.n.0613" wn="3" wnkey="function%1:04:00::" text="Evidence suggests that gain of function in PAX7 triggers neoplastic development by maintaining cells in a deregulated, undifferentiated and proliferative state, as is seen in alveolar rhabdomyosarcomas." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="9075" end="9079" sStart="null" offset="110" sid="r9.full.j.0984" wn="1" wnkey="full%3:00:00::" text="For the purposes of this analysis, smoking 4 hand rolled cigarettes, 4 cigars, or 4 pipes full of tobacco was considered equivalent to smoking 1 pack of industrial cigarettes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="5691" end="5697" sStart="null" offset="266" sid="r8.family.n.0117" wn="3" wnkey="family%1:14:04::" text="Although less frequent, 1p gains are also common to many tobacco-associated malignancies [ 11 13 14 15 16 ] . Work by Racz and colleagues suggest that PAX7 and ENO1 may be candidate oncogenes in this region [ 21 ] . PAX7 is part of a family of transcription factors known to be carcinogenic." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2156-3-22.anc" start="10506" end="10510" sStart="null" offset="0" sid="null" wn="5" wnkey="date%1:28:03::" text="Disease-free survival was determined as the differences between time zero (&lt;b&gt;date&lt;/b&gt; of first treatment) and the &lt;b&gt;date&lt;/b&gt; of first recurrence." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="8276" end="8282" sStart="null" offset="71" sid="r10.common.j.0638" wn="2" wnkey="common%3:00:01::" text="The oral cavity (17%) and laryngopharynx (83%) were the most common primary sites." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="8628" end="8639" sStart="null" offset="61" sid="r11.combination.n.0307" wn="1" wnkey="combination%1:14:00::" text="Radiation alone was utilized in 35 patients and in combination with chemotherapy in 33 patients." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="7841" end="7846" sStart="null" offset="236" sid="r10.board.n.0163" wn="1" wnkey="board%1:14:00::" text="Tumor samples from patients undergoing curative treatment for HNSCC were obtained at time of biopsy or surgical resection in the operating room, following guidelines established by the Institutional Review Board." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2156-3-22.anc" start="10079" end="10086" sStart="null" offset="112" sid="r11.absence.n.0572" wn="1" wnkey="absence%1:26:00::" text="Outcome of treatment was evaluated on the date of last patient contact by determining the presence or absence of cancer and the vital status (alive, dead, or unknown)." />
  </sentences>
</list>